EU Commission Targets Teva Over Alleged Copaxone Antitrust Breach
Teva Prepared To Use ‘All The Legal And Procedural Rights’ Available
A 2021 investigation into Teva’s conduct over its Copaxone multiple sclerosis drug by the European Commission has led to the firm receiving a statement of objections, which details a preliminary finding that the company violated EU antitrust laws.
